Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.
Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen …
Diagnostic Performance of Saline/Gel Sonovaginography in Assessment of Deep Infiltrating Endometriosis at Posterior Compartments; A Systematic Review and Meta-Analysis.
Sonovaginography (SVG) is a specialized ultrasound technique for evaluating certain locations of deep endometriosis (DE) in the posterior compartments. In this study, we assessed the diagnostic accuracy of saline/gel SVG …
Salivary miRNAs in the diagnosis of endometriosis An invited narrative scientific literature review, commissioned by European Board and College of Obstetrics and Gynaecology (EBCOG).
Endometriosis is a common gynaecological condition, the diagnosis of which has been made for many years through invasive procedures, such as laparoscopy. In recent years, non-invasive methods have been proposed, …
Endometriosis of the vermiform appendix: a rare cause of acute abdomen in women - case report and review of literature.
Appendicular endometriosis (AE) mimicking appendicitis is very rare. It has been reported only 44 times in the literature from 1975 to 2021. It is one of the causes of acute …
Catamenial Pneumothorax as an Underrecognized Manifestation of Thoracic Endometriosis: A 25-Year Single-Center Experience.
Objectives: Catamenial pneumothorax (CP) is a rare but clinically relevant cause of spontaneous pneumothorax (SP) in women and is associated with high recurrence rates. We hypothesized that CP is underrecognized …
Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) - Seeking Alpha
Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) Seeking Alpha